{
    "nct_id": "NCT04102007",
    "official_title": "A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Have a Suboptimal Response to Secukinumab or Ixekizumab and Are Switched to Risankizumab",
    "inclusion_criteria": "* Diagnosed with moderate to severe chronic plaque psoriasis for at least 6 months before Baseline (Week 0).\n* Participant must have been on labeled secukinumab or ixekizumab treatment for at least 6 months and are experiencing suboptimal response at time of Screening and Baseline visits.\n* Participant must have a Body Surface Area (BSA) 3%- <10% and Static Physician Global Assessment (sPGA) 2/3\n* Participant must be eligible for continued biologic therapy as assessed by the investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis, psoriatic arthritis.\n* Participant with active skin disease other than plaque psoriasis that could interfere with the assessment of plaque psoriasis.\n* History of any documented active or suspected malignancy or history of any malignancy within the last 5 years except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix.\n* History of major surgery within 12 weeks prior to Baseline or planned to be performed during the conduct of the trial as assessed by the investigator.\n* Participant with exposure to risankizumab or any IL-23 inhibitors.",
    "miscellaneous_criteria": ""
}